Impaired night vision affects 25 million Americans. Studies suggest topically reducing pupil size might help, especially for halo or starburst effects after refractive surgery. Medscape Medical News
Category: News
Open-Angle Glaucoma Tied to Early-Onset Alzheimer’s Disease
Open-angle glaucoma is linked to an increased risk for early-onset Alzheimer’s disease in middle-aged adults, especially men, a new study shows. Medscape Medical News
Diorasis Therapeutics Appoints Richard A. Kresch, MD, to Board of Directors
BOSTON–(BUSINESS WIRE)– #genetherapy–Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Richard A. Kresch, MD, to its Board of …
Abbelight kondigt een succesvolle Serie B-investering aan, geleid door AVANT BIO, om innovatie in beeldvorming te versnellen en toepassing in een ruimer klantenbestand op schaal te brengen
PARIJS–(BUSINESS WIRE)–Abbelight, een wereldleider en pionier in end-to-end oplossingen voor super-resolutiemicroscopie, kondigde vandaag een succesvolle Serie B-financieringsronde aan, geleid door AVANT BIO, een verstrekker van groeikapitaal die zic…
Abbelight kündigt erfolgreiche Serie-B-Finanzierungsrunde unter Federführung von AVANT BIO an, um Innovationen im Bereich Bildgebung voranzutreiben und deren Verbreitung bei einem größeren Kundenstamm zu fördern
PARIS–(BUSINESS WIRE)–Abbelight, ein Weltmarktführer und Pionier im Bereich End-to-End-Lösungen für die Superauflösungsmikroskopie, gab heute den erfolgreichen Abschluss einer Serie-B-Finanzierungsrunde unter der Leitung von AVANT BIO bekannt, einer …
Abbelight annuncia il successo dell'investimento di serie B guidato da AVANT BIO per accelerare l'innovazione dell'imaging e incrementare l'adozione da parte di un'ampia clientela
PARIGI–(BUSINESS WIRE)–Abbelight, un leader globale e un pioniere nelle soluzioni complete di microscopia a super risoluzione, oggi ha annunciato il successo di un round di finanziamento di serie B guidato da AVANT BIO, società di capitali di crescit…
Abbelight annonce le succès d’un investissement de série B mené par AVANT BIO afin d’accélérer l’innovation en imagerie et d’étendre son adoption à une clientèle plus large
PARIS–(BUSINESS WIRE)–Abbelight, leader mondial et pionnier dans le domaine des solutions complètes de microscopie à super-résolution, a annoncé aujourd’hui le succès d’un tour de financement de série B mené par AVANT BIO, une société de capital-inve…
Abbelight anuncia el exitoso cierre de una ronda de inversión Serie B liderada por AVANT BIO para acelerar la innovación en imagenología y ampliar su adopción a una base de clientes más amplia
PARÍS–(BUSINESS WIRE)–Abbelight, líder global y empresa pionera en soluciones integrales de microscopía de superresolución, anunció hoy el cierre exitoso de una ronda de financiación Serie B liderada por AVANT BIO, una firma de capital de crecimiento…
Advice on the Challenges in Managing Sjögren Disease
Dr Teja Kapoor urges early-career clinicians not to underestimate Sjögren’s disease, which requires thorough testing and multidisciplinary collaboration. Medscape
Overcoming Barriers in Sjögren Disease Care
Dr Teja Kapoor explores how cultural sensitivity and awareness can overcome barriers to timely Sjögren disease management in diverse communities. Medscape
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clin…
GenSight Biologics publie sa situation de trésorerie au 31 décembre 2025 et fait un point sur son activité
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de…
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (“GenSight Biologics” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for ret…
Eye Vessel Blockages: Early Warning for Alzheimer’s Disease?
Patients with retinal vascular occlusion had an elevated risk for Alzheimer’s disease and related dementias, new research shows. Medscape Medical News
Eye Vessel Blockages: Early Warning for Alzheimer’s Disease?
Patients with retinal vascular occlusion had an elevated risk for Alzheimer’s disease and related dementias, new research shows. Medscape Medical News
Riassunto: Pandorum Technologies e Nucelion Therapeutics annunciano una collaborazione strategica imperniata sulla produzione di una terapia rigenerativa dei tessuti basata su esosomi mirata alle patologie oculari nei mercati APAC
BANGALORE, India, e HYDERABAD, India–(BUSINESS WIRE)–Pandorum Technologies, specialista della medicina rigenerativa in fase clinica impegnato nello sviluppo di una piattaforma di nuova generazione per la rigenerazione programmabile dei tessuti, oggi …
National Vision Announces Participation in the 2026 ICR Conference
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the 2026 ICR Conference on Tuesday, January 13, 2026, at 9:00 a.m. Eastern Time….
Lions World Vision Institute Advances Accessible Care with Vision Health Center Groundbreaking in Ybor City
TAMPA, Fla.–(BUSINESS WIRE)–Lions World Vision Institute (LWVI) broke ground on its new $16 million Vision Health Center in Tampa’s historic Ybor City.
SpliceBio Appoints Don Munoz as Chief Financial Officer
BARCELONA–(BUSINESS WIRE)–SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer. Mr. Munoz, wh…
Eye Problems Tied to Osteonecrosis in Bisphosphonate Users
Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows. Medscape Medical News